Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:CCOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$181.89-2.6%$186.03$163.52▼$218.66$321.29B0.56.32 million shs22.88 million shsCCOICogent Communications$48.20+0.1%$49.73$43.65▼$86.76$2.38B0.72512,434 shs812,407 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.76%+0.97%+0.83%-8.80%+9.30%CCOICogent Communications+0.02%+3.06%-2.09%-21.78%-8.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.9559 of 5 stars3.45.04.23.93.02.51.3CCOICogent Communications4.5696 of 5 stars3.32.03.32.82.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.81Moderate Buy$211.2916.16% UpsideCCOICogent Communications 2.50Moderate Buy$75.7557.16% UpsideCurrent Analyst Ratings BreakdownLatest ABBV and CCOI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$205.006/9/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$204.005/14/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$210.00 ➝ $205.005/9/2025CCOICogent CommunicationsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$102.00 ➝ $75.005/9/2025CCOICogent CommunicationsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$71.00 ➝ $62.005/8/2025ABBVAbbVieBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.004/28/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.004/22/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$210.004/17/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$214.00 ➝ $214.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$57.37B5.60$14.64 per share12.42$1.90 per share95.73CCOICogent Communications$1.04B2.30$0.97 per share49.61$4.55 per share10.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3577.4013.011.237.31%412.03%13.11%7/24/2025 (Estimated)CCOICogent Communications-$204.07M-$4.01N/AN/AN/A-18.76%-70.29%-6.05%8/6/2025 (Estimated)Latest ABBV and CCOI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025ABBVAbbVie$3.24N/AN/AN/A$14.93 billionN/A5/8/2025Q1 2025CCOICogent Communications-$1.05-$1.09-$0.04-$1.09$250.81 million$247.05 million4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.61%N/A279.15%53 YearsCCOICogent Communications$4.048.38%N/AN/A 14 YearsLatest ABBV and CCOI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/20255/7/2025CCOICogent Communicationsquarterly$1.018.11%5/22/20255/22/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.760.64CCOICogent Communications13.891.491.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%CCOICogent Communications92.45%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%CCOICogent Communications11.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableCCOICogent Communications1,91649.34 million43.71 millionOptionableABBV and CCOI HeadlinesRecent News About These CompaniesOppenheimer & Co. Inc. Has $3.78 Million Holdings in Cogent Communications Holdings, Inc. (NASDAQ:CCOI)June 26 at 4:10 AM | marketbeat.comCCOI Cogent Communications Holdings, Inc. - Seeking AlphaJune 25 at 5:31 AM | seekingalpha.comConsolidated Planning Corp Grows Stock Position in Cogent Communications Holdings, Inc. (NASDAQ:CCOI)June 23, 2025 | marketbeat.com8,982 Shares in Cogent Communications Holdings, Inc. (NASDAQ:CCOI) Acquired by TrueMark Investments LLCJune 23, 2025 | marketbeat.comQ3 EPS Forecast for Cogent Communications Raised by AnalystJune 23, 2025 | americanbankingnews.comZacks Research Issues Positive Forecast for CCOI EarningsJune 23, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 11,328 Cogent Communications Holdings, Inc. (NASDAQ:CCOI)June 21, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) Sees Large Growth in Short InterestJune 18, 2025 | marketbeat.comCCOI Stock: 8%-Yielding Telecom Dividend Gem Hiding in Plain SightJune 17, 2025 | incomeinvestors.comInsider Selling: Cogent Communications Holdings, Inc. (NASDAQ:CCOI) CEO Sells 70,000 Shares of StockJune 16, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) CEO Sells $2,607,000.00 in StockJune 16, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) CEO Sells $2,668,050.00 in StockJune 13, 2025 | insidertrades.comDave Schaeffer Sells 55,000 Shares of Cogent Communications Holdings, Inc. (NASDAQ:CCOI) StockJune 12, 2025 | marketbeat.comGAMMA Investing LLC Has $3.94 Million Position in Cogent Communications Holdings, Inc. (NASDAQ:CCOI)June 12, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) Given Average Rating of "Moderate Buy" by BrokeragesJune 11, 2025 | marketbeat.comCCOI Q1 Earnings Call: Wavelength Expansion and Revenue Transition Define QuarterJune 10, 2025 | finance.yahoo.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) VP Sells $115,080.00 in StockJune 10, 2025 | insidertrades.comInsider Selling: Cogent Communications Holdings, Inc. (NASDAQ:CCOI) VP Sells 2,400 Shares of StockJune 9, 2025 | marketbeat.comThaddeus Gerard Weed Sells 4,900 Shares of Cogent Communications Holdings, Inc. (NASDAQ:CCOI) StockJune 9, 2025 | marketbeat.comDave Schaeffer Sells 80,000 Shares of Cogent Communications Holdings, Inc. (NASDAQ:CCOI) StockJune 9, 2025 | marketbeat.comCogent Communications Holdings, Inc. (NASDAQ:CCOI) CRO James Bubeck Sells 2,000 SharesJune 7, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABBV and CCOI Company DescriptionsAbbVie NYSE:ABBV$181.89 -4.90 (-2.62%) Closing price 03:59 PM EasternExtended Trading$182.50 +0.62 (+0.34%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Cogent Communications NASDAQ:CCOI$48.20 +0.04 (+0.08%) Closing price 04:00 PM EasternExtended Trading$48.20 -0.01 (-0.01%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access, private network, and data center colocation space services in North America, Europe, Oceania, South America, and Africa. The company offers on-net Internet access and private network services to law firms, financial services firms, and advertising and marketing firms, as well as heath care providers, educational institutions and other professional services businesses, other Internet service providers, telephone companies, cable television companies, web hosting companies, media service providers, mobile phone operators, content delivery network companies, and commercial content and application service providers. It also provides Internet access and private network services to customers that are not located in buildings directly connected to its network; and on-net services to customers located in buildings that are physically connected to its network. In addition, the company offers off-net services to corporate customers using other carriers' circuits to provide the last mile portion of the link from the customers' premises to the network. Further, it operates data centers that allow its customers to collocate their equipment and access the network. It serves primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations. Cogent Communications Holdings, Inc. was founded in 1999 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
